Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

NanoBiCar NanoBiCar: A novel immunotherapy for infectious diseases

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
1 February 2025 to 31 January 2028
Status
Running
EU funding
€3.6m
Total cost
€3.6m
Partners
12 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101186252

What the project is doing

In the project's own words, from its summary on CORDIS.

It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security.

A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority. Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar's long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field.

Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases will be used to eliminate intra (IC) and extracellular (EC) bacteria. These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/ acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host and the degree of immunocompetence.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator
Acosta Dominguez ArmandoSpainParticipant
Consorcio Centro De Investigacion Biomedica En Red M.p.MadridSpainThird party
Fundacion De La Comunidad Valenciana Centro De Investigacion Principe FelipeValenciaSpainThird party
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainParticipant
Sarmiento Garcia San Miguel Maria ElenaSpainParticipant
Victor Pallaruelo-SantamariaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Technion - Israel Institute of TechnologyHaifaIsraelParticipant
The Foundation for Medical Research Infrastructural Development and Health Services Next to the Medical Center Tel AvivTel AvivIsraelParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Cellularis Biomodels LdaIlhavoPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI